Literature DB >> 16497274

Effects of nicotine vary across two auditory evoked potentials in the mouse.

Kayla L Metzger1, Christina R Maxwell, Yuling Liang, Steven J Siegel.   

Abstract

BACKGROUND: Schizophrenia patients display sensory processing deficits, reduced alpha7-nicotine receptor expression, and increased incidence of smoking, prompting investigation of nicotine receptor agonists as possible treatments. We evaluated the effects of acute and chronic nicotine, using an animal model that incorporates genetic variation for sensory processing and nicotine sensitivity.
METHODS: C57BL/6J and DBA/2Hsd mice received 2 weeks of 4.2 mg/kg chronic nicotine or saline. Auditory evoked potentials were recorded before and after acute nicotine injection of 1.05 mg/kg on day 14, with a paired-click paradigm (S1/S2). Amplitude and gating of the P20 and N40 were compared between conditions.
RESULTS: Acute nicotine increased the amplitude and gating of the P20 and decreased the amplitude and gating of the N40 across all groups, primarily by acting on S1. Chronic nicotine attenuated the effects of acute nicotine on the N40.
CONCLUSIONS: Our data support the notion that the mouse P20 shares pharmacological response properties with the human P50. In addition, findings suggest that nicotine might increase the initial sensory response (S1), with a resulting improvement in gating of some components.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16497274     DOI: 10.1016/j.biopsych.2005.12.011

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  29 in total

1.  In vitro and in vivo demonstration of risperidone implants in mice.

Authors:  C Rabin; Y Liang; R S Ehrlichman; A Budhian; K L Metzger; C Majewski-Tiedeken; K I Winey; S J Siegel
Journal:  Schizophr Res       Date:  2007-08-31       Impact factor: 4.939

2.  Transdisciplinary Tobacco Use Research Centers: research achievements and future implications.

Authors:  Timothy B Baker; K Michael Cummings; Dorothy K Hatsukami; C Anderson Johnson; Caryn Lerman; Raymond Niaura; Stephanie S O'Malley
Journal:  Nicotine Tob Res       Date:  2009-07-24       Impact factor: 4.244

3.  NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia.

Authors:  John A Saunders; Michael J Gandal; Steve J Siegel
Journal:  Neurobiol Dis       Date:  2012-01-09       Impact factor: 5.996

4.  Maximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits.

Authors:  Karen E Stevens; Lijun Zheng; Kirsten L Floyd; Jerry A Stitzel
Journal:  Brain Res       Date:  2015-03-02       Impact factor: 3.252

5.  Mouse model predicts effects of smoking and varenicline on event-related potentials in humans.

Authors:  Noam D Rudnick; Andrew A Strasser; Jennifer M Phillips; Christopher Jepson; Freda Patterson; Joseph M Frey; Bruce I Turetsky; Caryn Lerman; Steven J Siegel
Journal:  Nicotine Tob Res       Date:  2010-04-15       Impact factor: 4.244

6.  Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma.

Authors:  J M Phillips; R S Ehrlichman; S J Siegel
Journal:  Neuroscience       Date:  2006-12-19       Impact factor: 3.590

Review 7.  Sensory gating: a translational effort from basic to clinical science.

Authors:  Howard C Cromwell; Ryan P Mears; Li Wan; Nash N Boutros
Journal:  Clin EEG Neurosci       Date:  2008-04       Impact factor: 1.843

Review 8.  Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

9.  Event-related oscillations in mice: effects of stimulus characteristics.

Authors:  Cindy L Ehlers; Jose R Criado
Journal:  J Neurosci Methods       Date:  2009-05-03       Impact factor: 2.390

Review 10.  Animal models and measures of perceptual processing in schizophrenia.

Authors:  Steven J Siegel; John C Talpos; Mark A Geyer
Journal:  Neurosci Biobehav Rev       Date:  2013-07-15       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.